NCT02135133 2026-03-17A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLDana-Farber Cancer InstitutePhase 2 Completed27 enrolled 7 charts
NCT03136146 2026-02-17Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaM.D. Anderson Cancer CenterPhase 2 Recruiting42 enrolled